Abstract
The CD19 molecule is ubiquitously expressed throughout all stages of B-cell differentiation, but is not found on haemopoietic stem cells. Since most B-cell leukaemias and lymphomas retain CD19 expression, it represents an excellent target for immunotherapy of these malignant disorders. Over the past 10 years, compelling pre-clinical evidence has accrued to indicate that expression of a CD19-targeted chimeric antigen receptor (CAR) in peripheral blood T-cells exerts therapeutic efficacy in diverse models of B-cell malignancy. Building on this, clinical studies are ongoing in several centres in which autologous CD19-specific CAR T-cells are undergoing evaluation in patients with acute and chronic B-cell leukaemia and refractory lymphoma. Early data have generated considerable excitement, providing grounds to speculate that CAR-based immunotherapy will radically alter existing management paradigms in B-cell malignancy. The focus of this mini-review is to evaluate these emerging clinical data and to speculate on clinical prospects for this new therapeutic modality.
Citations
Sep 10, 2014·Expert Review of Vaccines·Daphné BenteynKarine Breckpot
Oct 17, 2015·Immunopharmacology and Immunotoxicology·Doraid AlrifaiJohn Maher
Aug 5, 2017·Immunotherapy·David E Gilham, John Maher
Jun 27, 2015·European Journal of Haematology·Yangmin ZhuJing Huang
Feb 20, 2016·Archives of Pharmacal Research·Mi-Gyeong KimYu-Kyoung Oh
Jan 30, 2018·Japanese Journal of Clinical Oncology·Akira NakagawaraMasanori Nishi
Jun 2, 2018·Pharmaceutical Research·Paula SalmikangasPaul Chamberlain
Jul 3, 2019·Expert Opinion on Pharmacotherapy·Nazanin Majd, John de Groot
Apr 14, 2016·Biochemical Society Transactions·Lynsey M WhildingJohn Maher
Nov 14, 2015·Molecular Oncology·Lynsey M Whilding, John Maher
Apr 7, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jie-Ying XuQi-Jun Qian
Feb 13, 2018·Biotechnology & Genetic Engineering Reviews·Niaz MuhammadHaibin Xia
Aug 1, 2015·Blood·David Marc Davies, John Maher
Mar 11, 2015·Pediatric Blood & Cancer·Judith WeilandJosef Vormoor
Mar 26, 2015·Immunotherapy·Lynsey M Whilding, John Maher
Apr 16, 2016·Technology and Health Care : Official Journal of the European Society for Engineering and Medicine·N S SanddhyaP Shanthi
Jun 28, 2017·Immunotherapy·Anja Wegner
Sep 6, 2018·Molecular Cancer Therapeutics·Adam Ajina, John Maher
Jun 3, 2015·Disease Models & Mechanisms·Michaela Sharpe, Natalie Mount
Apr 18, 2014·Molecular Pharmaceutics·Haiming LuoWeibo Cai
Oct 19, 2021·Frontiers in Oncology·Gaia ZuccolottoAntonio Rosato